[1]
Eyüpoğlu, N.D., Çınar, O.E., Aksu, S., Büyükaşık, Y., Sayınalp, N., Demiroğlu, H., Göker, H., Özcebe, O.İ. and Haznedaroğlu, İ.C. 2022. Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate. Acta Medica. 53, 3 (Jun. 2022), 277–283. DOI:https://doi.org/10.32552/2022.ActaMedica.745.